Please ensure Javascript is enabled for purposes of website accessibility

Why Advaxis Stock Skyrocketed 13.8% Today

By Todd Campbell - Updated Apr 1, 2019 at 3:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap biotech reported encouraging news about its prostate cancer therapy.

What happened

After orchestrating a 15-1 reverse stock split to meet Nasdaq listing requirements last week, Advaxis (ADXS -8.57%) saw its shares rally 13.8% by 3:15 p.m. EDT following updated results from a trial evaluating its ADXS-PSA in prostate cancer. 

So what

The phase 1/2 study is evaluating ADXS-PSA alongside Merck's (MRK -0.46%) multibillion-dollar blockbuster Keytruda in heavily pre-treated patients with progressive and refractory metastatic, castration-resistant prostate cancer.

Letters shooting out of a megaphone held in a person's hand.

Image source: Getty Images.

The two-part trial includes an ADXS-PSA monotherapy arm and a combination arm. The combination data reported today showed that using the two therapies together resulted in a median overall survival rate of 21.1 months. The study's author, Dr. Mark N. Stein, said the data "compare favorably to standard-of-care therapy and to study results from similar unselected patient populations with bone-predominant disease."

The results were presented on Monday as part of a poster discussion at this year's American Association for Cancer Research annual meeting. 

Now what

ADXS-PSA is an immuno-oncology therapy that uses a listeria vaccine to deliver antigens to cancer cells to spark an immune response. The use of ADXS-PSA with Keytruda may help the immune system better spot and destroy cancer cells because Keytruda inhibits cancer's ability to hijack a mechanism that prevents the immune system from attacking it.

More research is necessary to confirm ADXS-PSA's effectiveness and safety, but the results are encouraging, particularly since Advaxis investors have endured a steady decline in share price since 2017. Given the amount of work left to be done and the company's high-risk track record, investors might be best served waiting until later-stage data is reported before jumping in and buying shares.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Advaxis, Inc. Stock Quote
Advaxis, Inc.
$0.06 (-8.57%) $0.01
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$90.41 (-0.46%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.